This Innovative Biotech Company Is Taking A Novel, Game-changing Approach To Eradicating Many Viruses, Including COVID-19…

• Over 30 years of experience in nanomedicine and antiviral therapy developments.
• Recently, the company has signed a licensing agreement with Karveer Meditech in India for the right to commercialize the company's COVID drugs NV-CoV-2 and NV-CoV-2-R.

• The evolving coronavirus shows no end in sight as there currently is no drug on the market that can cure as variants grow and evolve but the Company has fast moving drug candidates in development for treatment of SARS-CoV-2 patients 
• Possession of a strong, diverse, and promising product pipeline that addresses the world’s most infamous and infectious viruses. 
• Antiviral therapy and nanomedicine market is expected to experience exponential growth by 2026.

• NanoViricides, Inc.’s developments are sustainable beyond the COVID-19 as its diverse product pipeline targets several markets simultaneously: 
  • The global HIV drugs market is projected to grow from $30.46 billion in 2021 to $45.58 billion in 2028 at a CAGR of 5.9% in forecast period, 2021-2028.
  • The global influenza medication market size stood at USD 889.2 million in 2018 and is projected to reach USD 993.7 million by 2026, exhibiting a CAGR of 2.2% during the forecast period.
  • The shingles treatment market is expected to witness a high growth over the forecast period owing to the increasing prevalence of shingles .The global Shingles Treatments market is valued at million USD in 2017 and is expected to reach million USD by the end of 2023, growing at a CAGR of between 2017 and 2023.

See Below for Nanoviricides' Unique, Novel, Post-Immunotherapeutic “Bind-Encapsulate-Destroy” Mechanism

The company is developing nanotechnology-based biomimetic anti-viral medicines, called “nanoviricides.” In contrast to immunizations, A nanoviricide is a Nanomachine that completes the task of destroying a virus WITHOUT the help of the patient’s immune system.

This solves the key issues of drug resistance from viral mutations as nanoviricides drugs are empowered by biomimetic technology.

Designed by NanoViricides to “fool” a virus, the nanoviricides attach to the agent in the same way that the virus normally attaches to receptors on a cell surface. The nanoviricide dismantles and eliminates the virus’ effect on the host by directly attacking the virus at multiple points.

Upon these developments, consumers are projected to accept these drug products as they will offer greater personalization and accessibility to combating and eradicating viral infections even when viruses mutate. 

There is no denying that the world is changing… viruses are becoming more rampant and being ahead of the problem makes NNVC an exciting NYSE company that could see unstoppable growth ahead!

NanoViricides, Inc.’s innovative platform technology, R&D agility, flexible cGMP compliant facility, highly effective management team, and extensive anti-viral experience should place this company at the top of your “invest” watchlist!

NanoViricides, Inc. (NYSE American: NNVC)  is set to be a market disruptor in antiviral therapy and nanomedicine as it is on its way to successfully capturing a $80 B market with its cutting-edge nanoviricide® technology and drug products.

THIS IS A PAID ADVERTISEMENT

NO INVESTMENT ADVICE

This website is wholly owned by tradigital marketing group, inc. (d/b/a “tradigital ir”). Our reports are advertorials and are for general information purposes only.   never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our email list, as well as any social networking platforms we may use. please note well: tradigital ir and its employees are not  registered investment advisors, broker-dealers, or member(s) of any association for other research providers in any jurisdiction whatsoever. release of liability: through use of this website, viewing or using you agree to hold tradigital ir, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. tradigital ir encourages readers and investors to supplement the information in these reports with independent research and other professional advice. all information on featured companies is provided by the companies profiled or is available from public sources and tradigital ir makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. none of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. instead, tradigital ir strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. tradigital ir’s full disclosure is to be read and fully understood before using tradigital ir's website, or joining tradigital ir's email or text list. From time to time, tradigital ir will disseminate information about a company via website, email, sms, and other points of media. By viewing tradigital ir's website and/or reading tradigital ir's email or text newsletter you are agreeing ----> https://tradigitalir.com/disclaimer-tmg/. all potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation.  in compliance with section 17(b) of the securities act we are disclosing that we have been compensated a fee pursuant to an agreement between tradigital and nanoviricides, inc. tradigital was hired for a period beginning august 2019 and ending november 2019 to publicly disseminate information about nanoviricides, inc., via website, email, and sms. We were paid five thousand usd each month, via ach. We owned sixty thousand restricted common shares of nanoviricides, inc., which were eligible for sale on 02/13/2020. We sold this entire position as of 3/4/2022.  tradigital was hired for a period beginning january 2020 and ending january 2021 to publicly disseminate information about nanoviricides, inc., via website, email, and sms. We were paid five thousand usd each month, via ach. We owned fifty thousand restricted common shares of nanoviricides, inc., which were eligible for sale on 06/02/2020. We sold this entire position as of 3/4/2022. tradigital was hired to publicly disseminate information about nanoviricides, inc., via website, email, and sms. We were paid twenty-five thousand usd, via ach in february 2022 and the marketing will last for thirty days. We do not own any shares of nanoviricides, inc.  Readers are advised to review sec periodic reports: forms 10-q, 10k, form 8-k, insider reports, forms 3, 4, 5 schedule 13d. tradigital ir is compliant with the can-spam act of 2003. tradigital ir does not offer investment advice or analysis, and tradigital ir further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. it is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.the private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact may be forward-looking statements. forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. understand there is no guarantee past performance will be indicative of future results in preparing this publication, tradigital ir has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. investors should not rely on the information contained on this website. rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, tradigital ir and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. tradigital ir is not responsible for any claims made by the companies advertised herein, nor is tradigital ir responsible for any other promotional firm, its program, or its structure. tradigital ir is not affiliated with any exchange, electronic quotation system, the securities exchange commission, or finra.